Key points are not available for this paper at this time.
In this phase 2 study of anemia therapy in patients with end-stage renal disease on maintenance hemodialysis therapy, roxadustat was well tolerated and effectively maintained Hb levels.
Provenzano et al. (Tue,) studied this question.